Off-label prescribing in palliative care – a cross-sectional national survey of Palliative Medicine doctors

Abstract

Background:

Regulatory bodies including the European Medicines Agency register medications (formulation, route of administration) for specific clinical indications. Once registered, prescription is at clinicians’ discretion. Off-label use is beyond the registered use. While off-label prescribing may, at times, be appropriate, efficacy and toxicity data are often lacking.

Aim:

The aim of this study was to document off-label use policies (including disclosure and consent) in Australian palliative care units and current practices by palliative care clinicians.

Design:

A national, cross-sectional survey was conducted online following an invitation letter. The survey asked clinicians their most frequent off-label medication/indication dyads and unit policies. Dyads were classified into unregistered, off-label and on-label, and for the latter, whether medications were nationally subsidised.

Setting/participants:

All Australian palliative medicine Fellows and advanced trainees.

Results:

Overall, 105 clinicians responded (53% response rate). The majority did not have policies on off-label medications, and documented consent rarely. In all, 236 medication/indication dyads for 36 medications were noted: 45 dyads (19%) were for two unregistered medications, 118 dyads (50%) were for 26 off-label medications and 73 dyads (31%) were for 12 on-label medications.

Conclusions:

Off-label prescribing with its clinical, legal and ethical implications is common yet poorly recognised by clinicians. A distinction needs to be made between where quality evidence exists but registration has not been updated by the pharmaceutical sponsor and the evidence has not been generated. Further research is required to quantify any iatrogenic harm from off-label prescribing in palliative care.

Keywords

Off-label prescribing palliative care drug regulation physician knowledge iatrogenic harm

Get full access to this article

View all access options for this article.

References

Casali

. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2007; 18: 1923–1925.

Radley

Finkelstein

Stafford

. Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166: 1021–1026.

Douglas-Hall

Fuller

Gill-Banham

. An analysis of off-licence prescribing in psychiatric medicine. Pharm J 2001; 267: 890–891.

Herring

McManus

Weeks

. Off-label prescribing during pregnancy in the UK: an analysis of 18,000 prescriptions in Liverpool Women’s Hospital. Int J Pharm Pract 2010; 18: 226–229.

McIntyre

Conroy

Avery

. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 2000; 83: 498–501.

Mason

Pirmohamed

Nunn

. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 2012; 68: 21–28.

Conroy

Choonara

Impicciatore

. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000; 320: 79–82.

Mellor

Bensted

Chan

. Off label and unlicensed prescribing in a specialist oncology center in Australia. Asia-Pacific J of Clin Oncol 2009; 5: 242–246.

Poole

Dooley

. Off-label prescribing in oncology. Support Care Canc 2004; 12: 302–305.

10.

Abernethy

Raman

Balk

. Systematic review: reliability of compendia methods for off-label oncology indications. Ann Intern Med 2009; 150: 336–343.

11.

Brosgart

Mitchell

Charlebois

. Off-label drug use in human immunodeficiency virus disease. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 56–62.

12.

Atkinson

Kirkham

. Unlicensed uses for medication in a palliative care unit. Palliat Med 1999; 13: 145–152.

13.

Pavis

Wilcock

. Prescribing of drugs for use outside their licence in palliative care: survey of specialists in the United Kingdom. BMJ 2001; 323: 484–485.

14.

Avenel

Bomkratz

Dassieu

. The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr 2000; 7: 143–147.

15.

Cuzzolin

Zaccaron

Fanos

. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol 2003; 17: 125–131.

16.

Pandolfini

Impicciatore

Provasi

. Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatr 2002; 91: 339–347.

17.

Oncology ASoC. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol 2006; 24: 3206–3208.

18.

Soares

. ‘Off-label’ indications for oncology drug use and drug compendia: history and current status. J Oncol Pract 2005; 1: 102–105.

19.

Currow

Stevenson

Abernethy

. Prescribing in palliative care as death approaches. J Am Geriatr Soc 2007; 55: 590–595.

20.

Currow

THM

Abernethy

. Prescribing at times of clinical transition in chronic or progressive diseases. Int J Gerontol 2009; 3: 1–8.

21.

Dietz

Borasio

Schneider

. Medical errors and patient safety in palliative care: a review of current literature. J Palliat Med 2010; 13: 1469–1474.

22.

Good practice in prescribing medicines – guidance for doctors, http://www.gmc-uk.org/guidance/ethical_guidance/prescriptions_faqs.asp#10 (2008, accessed 12 June 2012).

23.

Von Elm

Altman

Egger

. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344–349.

24.

Ansani

Branch

Fedutes-Henderson

. United States medical practice summary: innovative off-label medication use. Am J Med Qual 2006; 21: 246–254.

25.

Toscani

Di Giulio

Campi

. Off-label prescriptions in Italian hospices: a national survey. J Pain Symptom Manage 2009; 38: 365–371.

26.

Anon. Use of approved drugs for unlabeled indications. FDA Drug Bull 1982; 12: 4–5.

27.

Shapiro

. Limiting physician freedom to prescribe a drug for any purpose: the need for FDA regulation. Northwest Uni Law Rev 1979; 73: 801–872.

28.

Chen

Wynia

Moloney

. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf 2009; 18: 1094–1100.

29.

Gazarian

Kelly

McPhee

. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006; 185: 544–548.

30.

Currow

. Why don’t we do more rigorous clinical research so that we can stop experimenting on patients? J Palliat Med 2010; 13: 636–637.

31.

Gazarian

. Why are children still therapeutic orphans? Austr Presc 2003; 26: 122–123.

32.

Mack

. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm 2003; 9: 559–568.

33.

Turner

Nunn

Fielding

. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88: 965–968.

34.

Neubert

Dormann

Weiss

. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 2004; 27: 1059–1067.

35.

Anon. Evidence of harm from off label or unlicensed medicines in children. London: European Medicines Agency (EMEA); 2004.

36.

Wilkes

Johns

. Informed consent and shared decision-making: a requirement to disclose to patients off-label prescriptions. PLoS Med 2008; 5: e223.

37.

Ansani

Sirio

Smitherman

. Designing a strategy to promote safe, innovative off-label use of medications. Am J Med Qual 2006; 21: 255–261.

38.

Blum

. Legal considerations in off-label medication prescribing. Arch Intern Med 2002; 162: 1777–1779.

39.

Thomadsen

Heaton

2nd Jani

. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121. Med Phys 2010; 37: 2300–2311.

40.

Henry

. Off-label prescribing. Legal implications. J Legal Med 1999; 20: 365–383.

41.

Anon. Prescription drugs: FDA’s oversight of the promotion of drugs for off-label uses. In: Office USGA (ed.) Report to the ranking member, Committee on Finance, US Senate, 2008.

42.

Anon. Good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices. Silver Spring, MD: Food and Drug Administration, 2009.

43.

Joseph

Deaton

Ehsan

. Enforcement related to off-label marketing and use of drugs and devices: where have we been and where are we going? J Health Life Sci Law 2009; 2: 73–108.

44.

Healy

Nutt

. Prescriptions, licences and evidence. Psychiatr Bull 1998; 22: 680–684.

45.

Wertheimer

. Off-label prescribing of drugs for children. Curr Drug Saf 2011; 6: 46–48.

46.

Bright

. Positive outcomes through the appropriate use of off-label prescribing. Arch Intern Med 2006; 166: 2554–2555; author reply 5.

47.

Joensuu

Roberts

Sarlomo-Rikala

. Effect of the Tyrosine Kinase Inhibitor STI571 in a patient with a Metastatic Gastrointestinal Stromal Tumor. N Engl J Med 2001; 344: 1052–1056.

48.

Abernethy

Currow

Frith

. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327: 523–528.

49.

Edlin

Round

Hulme

. Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. Br J Clin Pharmacol 2010; 70: 350–355.

50.

Fullerton

Busch

Frank

. The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. Med Care 2010; 48: 372–379.

51.

Oxman

Thomson

Davis

. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. CMAJ 1995; 153: 1423–1431.

52.

Flodgren

Parmelli

Doumit

. Local opinion leaders: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2011; 8: CD000125.

53.

Todd

Davies

. Use of unlicensed medication in palliative medicine. Palliat Med 1999; 13: 446.

54.

White

Gilshenan

Hardy

. A survey of the views of palliative care healthcare professionals towards referring cancer patients to participate in randomized controlled trials in palliative care. Support Care Cancer 2008; 16: 1397–1405.

55.

White

Hardy

Gilshenan

. Randomised controlled trials of palliative care – a survey of the views of advanced cancer patients and their relatives. Eur J Cancer 2008; 44: 1820–1828.

56.

White

Hardy

. What do palliative care patients and their relatives think about research in palliative care? – a systematic review. Support Care Cancer 2010; 18: 905–911.

57.

Largent

Miller

Pearson

. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch Intern Med 2009; 169: 1745–1747.

58.

Edersheim

Stern

. Liability associated with prescribing medications. Prim Care Companion J Clin Psychiatr 2009; 11: 115–119.

59.

Quill

Holloway

. Time-limited trials near the end of life. JAMA 2011; 306: 1483–1484.

60.

Abernethy

Currow

. Time-limited trials. JAMA 2012; 307: 33–34.

61.

Currow

Rowett

Doogue

. An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. J Palliat Med 2012; 15: 282–286.

62.

Price

Raebel

Conner

. Pharmaceuticals from development to practice: learnings from an online curriculum. Am J Manag Care 2009; 15: e109–e114.

63.

Eguale

Winslade

Hanley

. Enhancing pharmacosurveillance with systematic collection of treatment indication in electronic prescribing: a validation study in Canada. Drug Saf 2010; 33: 559–567.

64.

Landefeld

Steinman

. The neurontin legacy – marketing through misinformation and manipulation. N Engl J Med 2009; 360: 103–106.

65.

Van Zee

. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health 2009; 99: 221–227.

66.

Hébert

Stanbrook

. Indication creep: physician beware. CMAJ 2007; 177: 697.

67.

Currow

Shelby-James

Agar

. Planning phase III multi-site clinical trials in palliative care: the role of consecutive cohort audits to identify potential participant populations. Support Care Canc 2010; 18: 1571–1579.

68.

Walton

Schumock

Lee

. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy 2008; 28: 1443–1452.